Insulin Delivery Devices Market

The global insulin delivery devices market is projected to grow from USD 16.92 billion in 2026 to USD 26.37 billion by 2031, at a CAGR of 9.3% during the forecast period.

The insulin delivery devices market is growing because of the rising prevalence of diabetes, increasing demand for effective insulin administration, and technological advances in delivery systems. The growing adoption of insulin pens, insulin pumps, and automated insulin delivery systems is improving dosing convenience, treatment adherence, and diabetes management. Additionally, rising healthcare spending, expanding reimbursement coverage, and government initiatives to improve diabetes care are driving market expansion. Innovations in connected devices, smart insulin pens, needle technology, and tubeless insulin pumps are further enhancing patient convenience. Moreover, growing awareness of diabetes management and the need for personalized treatment approaches are creating opportunities for advanced insulin delivery technologies worldwide,

To know about the assumptions considered for the study download the pdf brochure

Some of the major players in the insulin delivery devices market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed (Switzerland), Medtronic (Ireland), Tandem Diabetes Care, Inc. (US), Sanofi (France), Eli Lilly and Company (US), Insulet Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Terumo Corporation (Japan), Medtrum Technologies Inc. (US), Wockhardt Limited (India), Nipro Corporation (Japan), CeQur Corporation (Switzerland), EOFlow Co., Ltd. (South Korea), Hindustan Syringes & Medical Devices Ltd. (HMD) (India), SOOIL Developments Co., Ltd (South Korea), mylife Diabetes Care AG (Switzerland), SUNGSHIM MEDICAL CO., LTD. (South Korea), B. Braun SE (Germany), Debiotech SA (Switzerland), Jiangsu Delfu Medical Device Co., Ltd (China), Haselmeier (Germany), and BIO-MED Healthcare Products Pvt. Ltd. (India). These leading manufacturers enhance their market positions through innovation, expansion, and collaboration. They actively invest in research and development to create advanced insulin delivery devices that improve patient care. Additionally, many companies are expanding through partnerships and acquisitions, allowing them to broaden their product ranges and enter new geographic markets. Several firms are also pursuing organic growth by introducing new products and seeking regulatory approval.

Embecta Corp. (US)

Embecta Corp. is a key player in the global insulin delivery devices market, with an extensive product portfolio, established manufacturing capabilities, and a strong international distribution network. With a century of experience in insulin administration, the company supplies pen needles, insulin syringes, and safety injection devices to more than 30 million people in over 100 countries. Its manufacturing facilities in the United States, Ireland, and China support large-scale production, with annual output of approximately 8 billion pen needles and insulin syringes. Embecta further strengthens its competitive position through product innovation, including safety-engineered devices, and strategic partnerships to advance automated insulin delivery technologies. Its established commercial network and diabetes-focused expertise reinforce its position in insulin administration.

Novo Nordisk A/S (Denmark)

Novo Nordisk A/S is a key player in the global insulin delivery devices market, supported by its diabetes care portfolio, which includes NovoPen® insulin pens, FlexPen®, FlexTouch®, and NovoFine® pen needles. These products support convenient and reliable insulin administration for people with diabetes. The company strengthens its competitive position through sustained investment in research and development, smart insulin delivery technologies, and strategic acquisitions, including BIOCORP Production SA, which enhanced its connected drug-delivery capabilities. Its extensive manufacturing infrastructure and commercial presence across approximately 170 markets support product availability and global reach.

Market Ranking

The insulin delivery devices market is competitive, with five main players collectively holding 25% to 50% of the total market share. The key players identified in the analysis are Embecta Corp. (US), Novo Nordisk A/S (Denmark), Medtronic plc (Ireland), Sanofi (France), and Eli Lilly and Company (US). Embecta Corp. is distinguished in the industry for its diverse range of advanced insulin delivery devices. Novo Nordisk A/S has a strong global presence with its advanced portfolio of insulin pens and needles. Medtronic plc is known for its wide product range worldwide, and the company uses both organic and inorganic strategies to maintain its market position. Sanofi and Eli Lilly stand out for their innovative insulin pens. The remaining 50% to 75% of the market share is held by various regional and emerging vendors, which creates opportunities for smaller players to establish a presence in the market.

Related Reports:

Insulin Delivery Devices Market by Type [Insulin Pens (Reusable, Disposable), Insulin Pumps (Tethered, Tubeless), Insulin Pen Needle (Standard, Safety), Insulin Syringes, Others], Application [Type 1 Diabetes, Type 2 Diabetes] - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]